ARTICLE | Finance
Nailing down NLRP3
Why investors backed $37M series A for inflammasome play NodThera
June 29, 2018 1:22 PM UTC
The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures.
F-Prime Capital Partners and founding investor Epidarex Capital also joined the round, which was announced on June 25...
BCIQ Company Profiles
BCIQ Target Profiles
NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1)